This translates to 1.5 million fewer CVD events over 10 years, with most preventable cases among men (2.2%) and white individuals (2.01%)
Notably, liraglutide (LEADER trial) and semaglutide (SUSTAIN-6 trial) have demonstrated cardiovascular benefits, including reductions in cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke
EC's phenotype becomes activated through interaction with leukocytes and platelets, the expression of several proinflammatory cytokines [TNF and interleukin-1 (IL-1)], and adhesion molecules
this hormone affects sleep and the circadian rhythm
With a standard 10 to 12 month review after that, most analysts expect approval no earlier than late 2027, with a launch more realistic in 2028
The tolerability question is not trivial